Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Raje on Key Challenges Faced in Multiple Myeloma

July 11th 2020

Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.

Dr. Kumar on the Rationale Behind the ENDURANCE Trial in Newly Diagnosed Myeloma

July 10th 2020

Shaji Kumar, MD, discusses the rationale behind the phase 3 ENDURANCE trial, which is comparing carfilzomib, lenalidomide, and dexamethasone with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Dr. Weisel on Interim Analysis With Isatuximab Plus KRd in High-Risk Myeloma

July 9th 2020

Katja Weisel, MD, discusses the interim analysis of the phase 2 GMMG-Concept trial with isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

July 8th 2020

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with relapsed/refractory multiple myeloma.

FDA Issues Clinical Hold on MELANI-01 Trial With UCARTCS1A in Myeloma

July 7th 2020

The FDA has issued a clinical hold on the phase 1 MELANI-01 trial evaluating the CAR T-cell product UCARTCS1A in the treatment of patient with relapsed/refractory multiple myeloma.

Dr. Braunstein on the Utility of Maintenance Therapy in Multiple Myeloma

July 7th 2020

Marc J. Braunstein, MD, PhD, discusses the utility of maintenance therapy in patients with multiple myeloma.

Dr. Yee on the Utility of Isatuximab in Combination Therapy for Relapsed/Refractory Myeloma

July 6th 2020

Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.

Dr. Munshi on T-Cell Persistence With Ide-Cel in R/R Multiple Myeloma

July 6th 2020

Nikhil C. Munshi, MD, discusses T-cell persistence with idecabtagene vicleucel demonstrated in the phase 2 KarMMA trial in patients with relapsed /refractory multiple myeloma.

Dr. Landgren on the Clinical Benefit of Idecabtagene Vicleucel in R/R Myeloma

July 1st 2020

C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.

Dr. Costello on the Role of Daratumumab in Multiple Myeloma

June 30th 2020

Caitlin Costello, MD, discusses the role of daratumumab in multiple myeloma.

Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma

June 30th 2020

Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.

Dr. Weisel on the Safety Profile of Isa-KRd in High-Risk Multiple Myeloma

June 30th 2020

Katja Weisel, MD, discusses the safety profile of isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

Dr. Landgren on Investigational Cellular Therapies in Multiple Myeloma

June 30th 2020

C. Ola Landgren, MD, PhD, discusses investigational cellular therapies in multiple myeloma.

Dr. Costa on CC-93269 in Relapsed/Refractory Multiple Myeloma

June 29th 2020

Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.

Belantamab Mafodotin Induces Responses in Relapsed/Refractory Myeloma, But Calls for Multidisciplinary Approach

June 29th 2020

Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.

Dr. Raje on the Rationale for CAR T-Cell Therapy in Multiple Myeloma

June 29th 2020

Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.

Dr. Mateos on the Significance of the CANOVA Trial in R/R t(11;14) Myeloma

June 29th 2020

María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.

Dr. Costello on Determining Proper Dosing of Carfilzomib in Relapsed/Refractory Myeloma

June 26th 2020

Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.

Multiple Myeloma Paradigm Moves Forward With Promising Portfolio

June 25th 2020

There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

June 25th 2020

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.